Literature DB >> 15617830

Cdk1 and Cdk2 complexes (cyclin dependent kinases) in apoptosis: a role beyond the cell cycle.

Roy M Golsteyn1.   

Abstract

The family of cyclin-dependent kinase complexes (Cdks) are well known for their role in the cell division cycle. What is less well known, however, is that Cdks also participate in a subset of apoptosis programs. Evidence for the role of Cdks in apoptosis comes from a variety of experimental approaches, including studies using genetic mutants, protein inhibitors, and chemical inhibitors of protein kinase activity. The precise role of Cdks in apoptosis remains to be defined, although one promising approach to clarify this question is to identify Cdk protein substrates during apoptosis. Currently a number of Cdk inhibitors are being tested in clinical trials. By understanding how Cdks function during apoptosis it may be possible to optimise the use of these inhibitors in treating human tumours by blocking proliferation but permitting apoptosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15617830     DOI: 10.1016/j.canlet.2004.08.005

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  37 in total

Review 1.  Cycling or not cycling: cell cycle regulatory molecules and adult neurogenesis.

Authors:  Pierre Beukelaers; Renaud Vandenbosch; Nicolas Caron; Laurent Nguyen; Gustave Moonen; Brigitte Malgrange
Journal:  Cell Mol Life Sci       Date:  2011-11-09       Impact factor: 9.261

2.  PAX7+ satellite cells in young and older adults following resistance exercise.

Authors:  Dillon K Walker; Christopher S Fry; Micah J Drummond; Jared M Dickinson; Kyle L Timmerman; David M Gundermann; Kristofer Jennings; Elena Volpi; Blake B Rasmussen
Journal:  Muscle Nerve       Date:  2012-05-29       Impact factor: 3.217

3.  Cytoplasmic initiation of cisplatin cytotoxicity.

Authors:  Fang Yu; Judit Megyesi; Peter M Price
Journal:  Am J Physiol Renal Physiol       Date:  2008-04-09

4.  Protection of cisplatin cytotoxicity by an inactive cyclin-dependent kinase.

Authors:  Rawad Hodeify; Judit Megyesi; Adel Tarcsafalvi; Robert L Safirstein; Peter M Price
Journal:  Am J Physiol Renal Physiol       Date:  2010-05-05

Review 5.  Cyclin-dependent kinase inhibitor drugs as potential novel anti-inflammatory and pro-resolution agents.

Authors:  A E Leitch; C Haslett; A G Rossi
Journal:  Br J Pharmacol       Date:  2009-09-23       Impact factor: 8.739

6.  Screening on human hepatoma cell line HepG-2 nucleus and cytoplasm protein after CDK2 silencing by RNAi.

Authors:  Xiaofang Han; Zhenyu Wang; Wenli Wang; Ruixia Bai; Pengwei Zhao; Jing Shang
Journal:  Cytotechnology       Date:  2014-05-07       Impact factor: 2.058

7.  Death-effector domain-containing protein DEDD is an inhibitor of mitotic Cdk1/cyclin B1.

Authors:  Satoko Arai; Katsuhisa Miyake; Renate Voit; Shino Nemoto; Edward K Wakeland; Ingrid Grummt; Toru Miyazaki
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-05       Impact factor: 11.205

8.  Cyclin-dependent kinase 2 signaling regulates myocardial ischemia/reperfusion injury.

Authors:  David A Liem; Peng Zhao; Ekaterini Angelis; Shing S Chan; Jun Zhang; Guangwu Wang; Cyril Berthet; Philipp Kaldis; Peipei Ping; W Robb MacLellan
Journal:  J Mol Cell Cardiol       Date:  2008-07-18       Impact factor: 5.000

9.  Jungermannenone A and B induce ROS- and cell cycle-dependent apoptosis in prostate cancer cells in vitro.

Authors:  Yan-Xia Guo; Zhao-Min Lin; Mei-Juan Wang; Yi-Wen Dong; Huan-Min Niu; Charles Yf Young; Hong-Xiang Lou; Hui-Qing Yuan
Journal:  Acta Pharmacol Sin       Date:  2016-05-02       Impact factor: 6.150

10.  Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML.

Authors:  Kensuke Kojima; Masaya Shimanuki; Masato Shikami; Michael Andreeff; Hideki Nakakuma
Journal:  Cancer Sci       Date:  2009-03-10       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.